BACKGROUND: Mitochondrial DNA (mtDNA) influences metabolic diseases and perhaps antiretroviral therapy (ART) complications. We explored associations between European mtDNA haplogroups and metabolic changes among A5142 participants. METHODS:Seven hundred and fifty-seven ART-naive patients were randomized to one of three class-sparing ART regimens including efavirenz and/or lopinavir/ritonavir with or without nucleoside reverse transcriptase inhibitors (NRTIs). Nonrandomized NRTIs included stavudine, tenofovir, or zidovudine, each with lamivudine. Fasting lipid profiles and whole-body dual-energy X-ray absorptiometry (DEXA) were performed. Nine European mtDNA haplogroups were determined for 231 self-identified non-Hispanic white individuals. Metabolic changes from baseline to 96 weeks were analyzed by haplogroup. RESULTS:Median age was 39 years, 9% were women, and 37, 32, and 30 were randomized to NRTI-containing regimens with either efavirenz or lopinavir/ritonavir, and an NRTI-sparing regimen, respectively. Among NRTI-containing regimens, 51% included zidovudine, 28% tenofovir, and 21% stavudine. Compared with other haplogroups, mtDNA haplogroup I (N = 10) had higher baseline non-HDL cholesterol [160 mg/dl (interquartile range 137-171) vs. 120 mg/dl (104-136); P = 0.005], a decrease in non-HDL cholesterol over 96 weeks [-14% (-20 to 6) vs. +25% (8 to 51); P < 0.001], tended to have more baseline extremity fat, and had more extremity fat loss by DEXA [-13% (-13 to 12) vs. +9% (-13 to 26); P = 0.08] and lipoatrophy (50 vs. 20%; P = 0.04). Haplogroup W (N = 5; all randomized to NRTI-sparing regimens) had the greatest increase in extremity fat [+35.5% (26.8 to 54.9); P = 0.02]. CONCLUSIONS:Lipids and extremity fat were associated with European mtDNA haplogroups in this HIV-infected population. These preliminary results suggest that mitochondrial genomics may influence metabolic parameters before and during ART.
RCT Entities:
BACKGROUND: Mitochondrial DNA (mtDNA) influences metabolic diseases and perhaps antiretroviral therapy (ART) complications. We explored associations between European mtDNA haplogroups and metabolic changes among A5142 participants. METHODS: Seven hundred and fifty-seven ART-naive patients were randomized to one of three class-sparing ART regimens including efavirenz and/or lopinavir/ritonavir with or without nucleoside reverse transcriptase inhibitors (NRTIs). Nonrandomized NRTIs included stavudine, tenofovir, or zidovudine, each with lamivudine. Fasting lipid profiles and whole-body dual-energy X-ray absorptiometry (DEXA) were performed. Nine European mtDNA haplogroups were determined for 231 self-identified non-Hispanic white individuals. Metabolic changes from baseline to 96 weeks were analyzed by haplogroup. RESULTS: Median age was 39 years, 9% were women, and 37, 32, and 30 were randomized to NRTI-containing regimens with either efavirenz or lopinavir/ritonavir, and an NRTI-sparing regimen, respectively. Among NRTI-containing regimens, 51% included zidovudine, 28% tenofovir, and 21% stavudine. Compared with other haplogroups, mtDNA haplogroup I (N = 10) had higher baseline non-HDL cholesterol [160 mg/dl (interquartile range 137-171) vs. 120 mg/dl (104-136); P = 0.005], a decrease in non-HDL cholesterol over 96 weeks [-14% (-20 to 6) vs. +25% (8 to 51); P < 0.001], tended to have more baseline extremity fat, and had more extremity fat loss by DEXA [-13% (-13 to 12) vs. +9% (-13 to 26); P = 0.08] and lipoatrophy (50 vs. 20%; P = 0.04). Haplogroup W (N = 5; all randomized to NRTI-sparing regimens) had the greatest increase in extremity fat [+35.5% (26.8 to 54.9); P = 0.02]. CONCLUSIONS:Lipids and extremity fat were associated with European mtDNA haplogroups in this HIV-infected population. These preliminary results suggest that mitochondrial genomics may influence metabolic parameters before and during ART.
Authors: D Crispim; N J R Fagundes; L H Canani; J L Gross; B Tschiedel; I Roisenberg Journal: Diabetes Res Clin Pract Date: 2006-06-19 Impact factor: 5.602
Authors: Richa Saxena; Paul I W de Bakker; Karyn Singer; Vamsi Mootha; Noel Burtt; Joel N Hirschhorn; Daniel Gaudet; Bo Isomaa; Mark J Daly; Leif Groop; Kristin G Ardlie; David Altshuler Journal: Am J Hum Genet Date: 2006-05-24 Impact factor: 11.025
Authors: Jeffrey A Canter; Gregory K Robbins; Doug Selph; David B Clifford; Asha R Kallianpur; Robert Shafer; Shawn Levy; Deborah G Murdock; Marylyn D Ritchie; David W Haas; Todd Hulgan Journal: J Infect Dis Date: 2010-06-01 Impact factor: 5.226
Authors: Todd Hulgan; David W Haas; Jonathan L Haines; Marylyn D Ritchie; Gregory K Robbins; Robert W Shafer; David B Clifford; Asha R Kallianpur; Marshall Summar; Jeffrey A Canter Journal: AIDS Date: 2005-09-02 Impact factor: 4.177
Authors: William Lewis; James J Kohler; Seyed H Hosseini; Chad P Haase; William C Copeland; Rachelle J Bienstock; Tomika Ludaway; Jamie McNaught; Rodney Russ; Tami Stuart; Robert Santoianni Journal: AIDS Date: 2006-03-21 Impact factor: 4.177
Authors: P F Chinnery; C Mowbray; S K Patel; J L Elson; M Sampson; G A Hitman; M I McCarthy; A T Hattersley; M Walker Journal: J Med Genet Date: 2007-06 Impact factor: 6.318
Authors: Andrea S Foulkes; David A Wohl; Ian Frank; Elaine Puleo; Stephanie Restine; Megan L Wolfe; Michael P Dube; Pablo Tebas; Muredach P Reilly Journal: PLoS Med Date: 2006-03 Impact factor: 11.069
Authors: Phumla Z Sinxadi; Joel A Dave; David C Samuels; Jeannine M Heckmann; Gary Maartens; Naomi S Levitt; C William Wester; David W Haas; Todd Hulgan Journal: AIDS Res Hum Retroviruses Date: 2013-03-15 Impact factor: 2.205
Authors: Phumla Z Sinxadi; Jan-Stefan van der Walt; Helen M McIlleron; Motasim Badri; Peter J Smith; Joel A Dave; Naomi S Levitt; Gary Maartens Journal: AIDS Res Ther Date: 2010-07-14 Impact factor: 2.250
Authors: Emily R Holzinger; Todd Hulgan; Ronald J Ellis; David C Samuels; Marylyn D Ritchie; David W Haas; Asha R Kallianpur; Cinnamon S Bloss; David B Clifford; Ann C Collier; Benjamin B Gelman; Christina M Marra; Justin C McArthur; J Allen McCutchan; Susan Morgello; David M Simpson; Donald R Franklin; Debralee Rosario; Doug Selph; Scott Letendre; Igor Grant Journal: J Neurovirol Date: 2012-10-17 Impact factor: 2.643